Merck halts development of osteoporosis drug in light of stroke risk

Kenilworth, N.J.-based Merck will stop developing its experimental drug to treat osteoporosis following an analysis showing the drug is tied to increased stroke risk.

The drug, odanacatib, limits risk of osteoporotic fractures. However, a late-stage study found postmenopausal women were at an increased risk of stroke when taking the drug. Merck said Friday the findings do not support additional development or regulatory approval.

More articles about supply chain:
Mylan coupled executive pay with high profit targets: 7 things to know
Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics for $624M
Roche seeks FDA approval for additional use of cancer drug


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars